Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovaBridge BiosciencesNBP · Entity 6324 | Chief Bus. Development Officer | September 09, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovaBridge Biosciences
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 266,467 |
Reported balance
After 2026-09-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-09 · Sale · Disposed 107,978 · Balance 266,467 F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2: The Reporting Person sold 46,947 ADSs representing approximately 107,978 ordinary shares in connection with the partial vesting of a restricted stock unit award on September 3, 2026, solely to satisfy tax withholding obligations incurred in connection with the vesting. F3: Reported securities are represented by 46,947 ADSs. F4: Reported sales price represents the converted sales price of the ADSs of $1.6908. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
F2: The Reporting Person sold 46,947 ADSs representing approximately 107,978 ordinary shares in connection with the partial vesting of a restricted stock unit award on September 3, 2026, solely to satisfy tax withholding obligations incurred in connection with the vesting.
F3: Reported securities are represented by 46,947 ADSs.
F4: Reported sales price represents the converted sales price of the ADSs of $1.6908.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 11, 2026 20:30 UTC | NovaBridge Biosciences NBP · Entity 6324 | SaleOrdinary Shares | 107,978 | $0.74 | $79,903.72 |
DisclosureSEC source: 0002109966-26-000008 · form4-09112026_040901.xml · nonDerivative · entry 1 Cao Sean Wuxiong · CIK 0002109966 · Chief Bus. Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,467 F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2 · kind: The Reporting Person sold 46,947 ADSs representing approximately 107,978 ordinary shares in connection with the partial vesting of a restricted stock unit award on September 3, 2026, solely to satisfy tax withholding obligations incurred in connection with the vesting. F3 · shares: Reported securities are represented by 46,947 ADSs. F4 · price: Reported sales price represents the converted sales price of the ADSs of $1.6908. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 21:51 UTC | NovaBridge Biosciences NBP · Entity 6324 | Exercise / conversionRestricted Share Units · Derivative | 45,320 | $0.00 | $0.00 |
DisclosureSEC source: 0002109966-26-000006 · form4-09082026_090957.xml · derivative · entry 4 Cao Sean Wuxiong · CIK 0002109966 · Chief Bus. Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,960 Underlying: Ordinary Shares · 45,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F6 · derivative.exercise_date: On June 22, 2026, the Reporting Person was granted 181,280 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on September 3, 2026 and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month. F6 · derivative.expiration_date: On June 22, 2026, the Reporting Person was granted 181,280 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on September 3, 2026 and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 21:51 UTC | NovaBridge Biosciences NBP · Entity 6324 | Exercise / conversionRestricted Share Units · Derivative | 102,233 | $0.00 | $0.00 |
DisclosureSEC source: 0002109966-26-000006 · form4-09082026_090957.xml · derivative · entry 3 Cao Sean Wuxiong · CIK 0002109966 · Chief Bus. Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 306,700 Underlying: Ordinary Shares · 102,233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F5 · derivative.exercise_date: On September 3, 2025, the Reporting Person was granted 408,933 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month. F5 · derivative.expiration_date: On September 3, 2025, the Reporting Person was granted 408,933 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 21:51 UTC | NovaBridge Biosciences NBP · Entity 6324 | Exercise / conversionOrdinary Shares | 104,236 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002109966-26-000006 · form4-09082026_090957.xml · nonDerivative · entry 2 Cao Sean Wuxiong · CIK 0002109966 · Chief Bus. Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F4 · shares: Reported securities are represented by 45,320 ADSs. F3 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 21:51 UTC | NovaBridge Biosciences NBP · Entity 6324 | Exercise / conversionOrdinary Shares | 235,136 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002109966-26-000006 · form4-09082026_090957.xml · nonDerivative · entry 1 Cao Sean Wuxiong · CIK 0002109966 · Chief Bus. Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2 · shares: Reported securities are represented by 102,233 ADSs F3 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 23:22 UTC | NovaBridge Biosciences NBP · Entity 6324 | Grant2025 Employee Share Option (right to buy) · Derivative | 181,290 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0002109966-26-000004 · form4-06242026_110623.xml · derivative · entry 2 Cao Sean Wuxiong · CIK 0002109966 · Director · Chief Bus. Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,290 Underlying: Ordinary Shares · 181,290 shares Expires 2036-06-22 F2 · derivative.exercise_price: Number of underlying securities and exercise price expressed in terms of ADSs. F2 · shares: Number of underlying securities and exercise price expressed in terms of ADSs. F5 · derivative.exercise_date: The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$8.00. F4 · derivative.underlying: The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2 · derivative.underlying_shares: Number of underlying securities and exercise price expressed in terms of ADSs. F2 · balance_after: Number of underlying securities and exercise price expressed in terms of ADSs. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 23:22 UTC | NovaBridge Biosciences NBP · Entity 6324 | GrantRestricted Share Units · Derivative | 181,280 | $0.00 | $0.00 |
DisclosureSEC source: 0002109966-26-000004 · form4-06242026_110623.xml · derivative · entry 1 Cao Sean Wuxiong · CIK 0002109966 · Director · Chief Bus. Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,280 Underlying: Ordinary Shares · 181,280 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one American Depositary Shares ("ADS"). F2 · shares: Number of underlying securities and exercise price expressed in terms of ADSs. F3 · derivative.exercise_date: The RSUs shall vest over four years, with one-fourth vesting on September 3, 2026 and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month. F3 · derivative.expiration_date: The RSUs shall vest over four years, with one-fourth vesting on September 3, 2026 and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month. F4 · derivative.underlying: The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2 · derivative.underlying_shares: Number of underlying securities and exercise price expressed in terms of ADSs. F2 · balance_after: Number of underlying securities and exercise price expressed in terms of ADSs. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC | NovaBridge Biosciences NBP · Entity 6324 | SaleOrdinary Shares | 21,399 | $1.99 | $42,584.01 |
DisclosureSEC source: 0001193125-26-228889 · ownership.xml · nonDerivative · entry 1 Cao Sean Wuxiong · CIK 0002109966 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,073 F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2 · kind: The reporting person sold 9,304 ADSs representing approximately 21,399 ordinary shares in connection with the partial vesting of a restricted stock unit award on January 31, 2026, solely to satisfy tax withholding obligations incurred in connection with the vesting. F3 · price: Price expressed in terms of ADSs. F4 · balance_after: The reported securities are represented by 15,249 ADSs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.